Mesable OD Tablet contains Mesalamine 1200 mg, an anti-inflammatory agent specifically formulated for the treatment and maintenance of remission in inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Mesalamine, also known as 5-aminosalicylic acid (5-ASA), works locally in the colon to reduce inflammation by inhibiting the production of prostaglandins and leukotrienes—chemicals that contribute to the inflammatory response in the gut lining.
This extended-release formulation ensures a consistent therapeutic effect throughout the day, providing sustained relief from symptoms like abdominal pain, rectal bleeding, diarrhea, and urgency. Mesable OD is designed to release the active ingredient in the terminal ileum and colon, targeting the site of inflammation directly and minimizing systemic side effects.
The tablet is suitable for long-term management, especially in patients with mild to moderate ulcerative colitis. It not only helps induce remission but also significantly reduces the risk of relapse when taken regularly. The delayed-release technology optimizes drug delivery and patient compliance by allowing once-daily dosing.
Mesalamine is generally well-tolerated, and Mesable OD’s high-dose, once-daily convenience is particularly helpful for individuals requiring long-term maintenance therapy. It is considered a first-line option in ulcerative colitis management due to its safety profile and proven efficacy.
The formulation is free from systemic corticosteroids, making it a safer alternative for long-term use without the associated risks of steroid dependence or immunosuppression. However, patients should be regularly monitored, especially those with a history of renal dysfunction.